Mitsubishi Tanabe Pharma Development America

Mitsubishi Tanabe Pharma Development America (MTDA) is the U.S.-based clinical development arm of Mitsubishi Tanabe Pharma Corporation, a leading Japanese pharmaceutical company. Headquartered in Jersey City, New Jersey, MTDA focuses on advancing innovative therapies through clinical trials to address significant unmet medical needs in neurology, immunology, and rare diseases. The company played a pivotal role in the development and FDA approval of Radicava (edaravone) for Amyotrophic Lateral Sclerosis (ALS), marking a major milestone in neurology. MTDA manages a robust pipeline that includes advanced candidates for Parkinson's disease and erythropoietic protoporphyria. By integrating global research capabilities with local clinical expertise, MTDA strives to deliver life-changing treatments to patients across North America.